Does vaginal estrogen prevent urinary tract infections?
Yes. For postmenopausal women who keep getting urinary tract infections, low-dose vaginal estrogen lowers how often those infections come back, and it carries the strongest evidence grade of any recommendation in the 2025 genitourinary syndrome of menopause (GSM) guideline.
How it works
After menopause, falling estrogen thins the tissue of the vagina and urethra and shifts the vaginal environment. The lactobacilli that keep the pH low give way to a more diverse mix of bacteria and a higher pH, and that change makes it easier for bad bacteria to take hold. Vaginal estrogen reverses those changes. Restoring the tissue and helping lactobacilli return lowers the conditions that let infection start, which is why treating the underlying tissue changes, sometimes still called vaginal atrophy, also lowers infection risk.
What the guidelines recommend
The AUA/SUFU/AUGS 2025 GSM guideline recommends that clinicians recommend local low-dose vaginal estrogen to peri- and postmenopausal women with recurrent UTIs to reduce the risk of future infections. It grades this a Moderate Recommendation, Evidence Level Grade B, which is the highest evidence grade anywhere in that guideline. The separate AUA/CUA/SUFU recurrent UTI guideline reaches the same conclusion, advising vaginal estrogen for all peri- and postmenopausal women with recurrent UTIs when there is no contraindication, also at Grade B.
How well it works
In the recurrent UTI guideline’s pooled analysis of four trials (313 women, mean age 65 and older), vaginal estrogen carried a relative risk of 0.59 (95% CI 0.35 to 1.01) for having at least one more UTI. The best single trial, using estriol vaginal cream, cut annualized infections from 5.9 to 0.5 episodes per year (RR 0.25; 95% CI 0.13 to 0.50), and the women on estrogen needed far fewer days of antibiotics over eight months (6.9 versus 32.0). Outside the trials, a Kaiser Permanente review of 5,600 women found mean UTI frequency fell from 3.9 to 1.8 per year, a 52% reduction.
Vaginal estrogen, not systemic estrogen
This benefit is specific to local, vaginal estrogen. Systemic estrogen, meaning pills or patches, has not been shown to prevent recurrent UTIs and is not recommended for that purpose. Low-dose vaginal estrogen acts locally with minimal systemic absorption, so it needs no added progestogen and no routine endometrial monitoring.
What to expect
Vaginal estrogen is preventive. It is not a treatment for an active infection. Active bladder infections should be treated with a short course of antibiotics. The benefit of topical vaginal estrogen also builds over months rather than days. The trials that showed fewer infections measured results over roughly four to eight months of use, and the tissue changes that drive the effect typically take one to three months to develop, so it is fair to judge it over an extended period.
Does the formulation matter
Cream, tablet, insert, and ring are all reasonable choices, and there is not enough data to say that one formulation prevents more UTIs than another. What matters more is using it consistently. In the head-to-head randomized trial, adherence was 100% with the estradiol ring versus 57% to 60% with the cream, and the ring’s better infection results likely came from that better adherence. The ring is replaced every three months, so it removes the twice-weekly dosing that people often forget.
How I approach it
For a postmenopausal patient whose UTIs keep returning, vaginal estrogen is usually the first preventive step I bring up. It works quietly in the background, so I set the expectation up front that we are judging it over the next several months.
References
- Kaufman MR, Ackerman AL, Amin KA, et al. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline. American Urological Association. 2025.
- Anger J, Lee U, Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019, Confirmed 2022, Amended 2025). American Urological Association / Canadian Urological Association / SUFU. 2019.
- Ferrante KL, Wasenda EJ, Jung CE, et al. Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial. Female Pelvic Medicine & Reconstructive Surgery. 2021. doi:10.1097/SPV.0000000000000749
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics & Gynecology. 2014. doi:10.1097/AOG.0000000000000526
← Learn more about Vaginal Estrogen